AI Echocardiographic Screening for Cardiac Amyloidosis

N/A

Waitlist Available

Led By David Ouyang, MD

Research Sponsored by Cedars-Sinai Medical Center

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Must not have

Patients that decline consent

Timeline

Screening 3 weeks

Treatment Varies

Follow Up 1 year

Awards & highlights

No Placebo-Only Group

Summary

"This trial discusses how machine learning models can be used to analyze echocardiograms and accurately identify features that may be missed by human experts. The study focuses on cardiac amyloidosis, a rare disease

Who is the study for?

This trial is for individuals who may have cardiac amyloidosis, a rare heart condition often mistaken for other types of heart failure. It's especially aimed at those with symptoms or conditions that could be related to this disease and would typically undergo echocardiography.

What is being tested?

The trial is testing an AI algorithm called EchoNet-LVH designed to improve the detection of cardiac amyloidosis using routine echocardiogram images. The goal is to see if this technology can more accurately identify patients who need further screening.

What are the potential side effects?

Since the intervention involves assessment with an AI tool rather than medication or invasive procedures, there are no direct side effects from the EchoNet-LVH itself.

Eligibility Criteria

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:

Select...

I have chosen not to give my consent for participation.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ 1 year

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~1 year

This trial's timeline: 3 weeks for screening, Varies for treatment, and 1 year for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.

Primary study objectives

Positive Predictive Value

Secondary study objectives

Number of Participants with Heart Failure Hospitalization

Time to Diagnosis from Echocardiogram Study to Clinical Diagnosis

Awards & Highlights

No Placebo-Only Group

All patients enrolled in this study will receive some form of active treatment.

Trial Design

1Treatment groups

Experimental Treatment

Group I: Suspicious by EchoNet-LVH AlgorithmExperimental Treatment1 Intervention

Each potential participant identified by automated AI-enhanced echocardiogram review will be chart reviewed by each site's CA experts for appropriateness of enrollment and clinican suspicion for CA. Based on the judgement of CA experts, potential participants that meet eligibility criteria will be called to be consented, followed in the study, and referred to see the CA expert.

0 / 1Eligibility criteria met